首页> 外文OA文献 >Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)
【2h】

Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)

机译:临床试验部位登记对患者特征,方案完成和终点的影响:ASCEND-HF试验的启示(奈西立肽治疗失代偿性心力衰竭的临床有效性的急性研究)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background Most international acute heart failure trials have failed to show benefit with respect to key end points. The impact of site enrollment and protocol execution on trial performance is unclear. Methods and Results We assessed the impact of varying site enrollment volume among all 7141 acute heart failure patients from the ASCEND-HF trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Overall, 398 sites enrolled 1 patient, and median enrollment was 12 patients (interquartile range, 5-23). Patients from high enrolling sites (>60 patients/site) tended to have lower ejection fraction, worse New York Heart Association functional class, and lower utilization of guideline-directed medical therapy but fewer comorbidities and lower B-type natriuretic peptide level. Every 10 patient increase (up to 100 patients) in site enrollment correlated with lower likelihood of protocol noncompletion (odds ratio, 0.93; 95% confidence interval [CI], 0.89-0.98). After adjustment, increasing site enrollment predicted higher risk of persistent dyspnea at 6 hours (per 10 patient increase: odds ratio 1.02; 95% CI, 1.01-1.03) but not at 24 hours (odds ratio, 0.99; 95% CI, 0.98-1.00). Higher site enrollment was independently associated with lower risk of 30-day death or rehospitalization (per 10 patient increase: odds ratio, 0.98, 95% CI, 0.96-0.99) but not 180-day mortality (hazard ratio, 0.99; 95% CI, 0.98-1.01). The influence of increasing site enrollment on clinical end points varied across geographic regions with strongest associations in Latin America and Asia-Pacific (all interaction P Conclusions In this large, acute heart failure trial, site enrollment correlated with protocol completion and was independently associated with trial end points. Individual and regional site performance present challenges to be considered in design of future acute heart failure trials. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00475852.
机译:背景技术大多数国际急性心力衰竭试验未能在关键终点方面显示出益处。尚不清楚站点注册和协议执行对试验性能的影响。方法和结果我们评估了ASCEND-HF试验(奈西立肽在代偿性心力衰竭临床有效性的急性研究)中对7141例急性心力衰竭患者进行不同部位登记量的影响。总共398个地点招募了1名患者,中位招募是12名患者(四分位间距为5-23)。高入院位点(> 60位患者/位点)的患者倾向于有较低的射血分数,较差的纽约心脏协会功能等级,较低的指导性药物治疗利用率,但合并症较少且B型利钠肽水平较低。现场登记每增加10名患者(最多100名患者),则方案未完成的可能性降低(赔率,0.93; 95%置信区间[CI],0.89-0.98)。调整后,增加的部位登记量预测在6小时出现持续呼吸困难的风险更高(每10例患者增加:优势比1.02; 95%CI,1.01-1.03),但在24小时则没有(发生几率0.99,95%CI 0.98- 1.00)。较高的入院率与较低的30天死亡或再次住院风险(每增加10位患者:比值比,0.98,95%CI,0.96-0.99)独立相关,但与180天死亡率(危险比,0.99; 95%CI)无关,0.98-1.01)。站点注册增加对临床终点的影响在拉丁美洲和亚太地区之间关联最强的地理区域中有所不同(所有交互作用P结论在这项大型急性心力衰竭试验中,站点注册与方案完成相关,并且与试验独立相关终点:个人和区域站点的性能提出了在设计未来急性心力衰竭试验时要考虑的挑战临床试验注册URL:http://www.clinicaltrials.gov。唯一标识符:NCT00475852。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号